Abstract:Although the robust antidepressant effects of the N -methyl- d -aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although ( R )-ketamine is a less potent NMDAR antagonist than ( S )-ketamine, ( R )-ketamine has shown more marked and longer-lasting antidepressant-like effects than ( S )-ketamine in several animal models of depression. Furthermore, non-ketamine NMDAR antagonists do not exhibit robust ketamine-like antidepressant effects in patients with depression. These findings suggest that mechanisms other than NMDAR inhibition play a key role in the antidepressant effects of ketamine. Duman’s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine. However, we reported that mTORC1 serves a role in the antidepressant effects of ( S )-ketamine, but not of ( R )-ketamine, and that extracellular signal-regulated kinase possibly underlie the antidepressant effects of ( R )-ketamine. Several lines of evidence have demonstrated that brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), are crucial in the antidepressant effects of ketamine and its two enantiomers, ( R )-ketamine and ( S )-ketamine, in rodents. In addition, (2 R ,6 R )-hydroxynormetamine [a metabolite of ( R )-ketamine] and ( S )-norketamine [a metabolite of ( S )-ketamine] have been shown to exhibit antidepressant-like effects on rodents through the BDNF–TrkB cascade. In this review, we discuss recent findings on the molecular and cellular mechanisms underlying the antidepressant effects of enantiomers of ketamine and its metabolites. It may be time to reconsider the hypothesis of NMDAR inhibition and the subsequent AMPAR activation in the antidepressant effects of ketamine.

Advances in NMDA receptors-related antidepressants

Design, Synthesis and Biological Evaluation of Novel Ketamine Derivatives as NMDAR Antagonists

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

The N-methyl-d-aspartate receptor hypothesis of ketamine's antidepressant action: evidence and controversies

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

NMDA antagonist treatment of depression

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

Targeting of NMDA Receptors in the Treatment of Major Depression.

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

A Bright Future of Researching AMPA Receptor Agonists for Depression Treatment

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions

Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

New use of old drug:introductiono f the antidepressant effects of ketamine and the underlying mechanisms